GENFIT, a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, announced the appointment of Dr. Pejvack Motlagh, the new Chief Medical Officer of GENFIT.
Member of the Executive Committee, Dr. Motlagh will oversee the strategy, direction, and execution of GENFIT’s clinical development plans and lead the Clinical (Operations and Strategy), Biometrics and Pharmacovigilance teams.
With over 20 years of experience in the pharmaceutical and biotechnology industry, Dr. Motlagh brings extensive expertise in drug development strategy across multiple therapeutic areas. His leadership will be instrumental in shaping GENFIT’s clinical development programs and advancing its pipeline.
Read More: SalesTechStar Interview with Jonathon Blackburn, CRO at Fyxer AI
Prior to joining GENFIT, Dr. Motlagh served as CMO at Egle Therapeutics, a company focused on therapies targeting regulatory T cells for oncology and autoimmune diseases. He also held the role of CMO at Mablink Biosciences, a biotechnology company specializing in next-generation antibody-drug conjugates (ADCs). Earlier in his career, Dr. Motlagh contributed to the success of several large pharmaceutical organizations, playing a key role in advancing compounds from early phase clinical development up to commercialization.
Dr. Pejvack Motlagh, Chief Medical Officer of GENFIT, commented: “I am thrilled to join GENFIT at a pivotal moment, as Acute on-Chronic Liver Failure becomes an increasingly important focus among the liver disease community. The company’s commitment to innovation and patient-centric development aligns perfectly with my own values. I look forward to working with the team to drive forward our clinical programs and make a meaningful impact in areas of high unmet medical need.”
Pascal Prigent, CEO of GENFIT, stated: “We are delighted to welcome Pejvack to GENFIT. His deep expertise in clinical development and proven leadership in both large pharmaceutical and innovative biotech companies will be invaluable as we continue to advance our pipeline and deliver on our mission to bring transformative therapies to patients.”
Read More: The Autonomous Sales Stack: How AI Workflows Are Eliminating Manual Friction In Salestech
